ABBV 453
Alternative Names: ABBV-453Latest Information Update: 24 Jul 2024
At a glance
- Originator AbbVie
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic lymphocytic leukaemia; Multiple myeloma
Most Recent Events
- 14 Jun 2024 Phase-I clinical trials in Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in Israel, USA (PO) (NCT06291220)
- 04 Mar 2024 AbbVie plans a phase I trial for Chronic lymphocytic leukaemia(Second-line therapy or greater, Combination therapy) in USA and Israel (PO, tablet) in June 2024 (NCT06291220)
- 17 May 2022 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (PO) (NCT05308654)